Yi-Hsun Ho

Title: The Innovations of Yi-Hsun Ho

Introduction

Yi-Hsun Ho is a prominent inventor based in Taipei, Taiwan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of histone deacetylase (HDAC) inhibitors. His work focuses on creating compounds that can effectively target various types of cancer.

Latest Patents

Yi-Hsun Ho holds a patent for histone deacetylases (HDACs) inhibitors. The patent describes a structural formula where moiety A is a benzene ring, optionally substituted, and moiety B is either a benzene ring attached at the 1,4 or 1,3 position, or a cyclohexane ring attached at the 1,4 position, also optionally substituted. The inhibitors have shown cytotoxic effects on various cancer cell lines. They are particularly useful for treating tumors associated with the deregulation of histone deacetylase activity. The HDAC inhibitors are effective against glioma, breast cancer, colon cancer, lung cancer, and several other malignancies.

Career Highlights

Yi-Hsun Ho is affiliated with Annji Pharmaceutical Co., Ltd., where he continues to innovate in the field of cancer treatment. His research has led to advancements in understanding how HDAC inhibitors can be utilized in therapeutic applications.

Collaborations

He has collaborated with notable colleagues such as Ji-Wang Chern and Chao-Wu Yu, contributing to the collective knowledge and advancements in their field.

Conclusion

Yi-Hsun Ho's work in developing HDAC inhibitors represents a significant step forward in cancer treatment. His innovative approach and dedication to research continue to impact the pharmaceutical industry positively.